Neukine 300 Mcg Pfs

Filgrastim belongs to a class of medications known as granulocyte colony-stimulating factors (G-CSFs), which work by stimulating the bone marrow to produce more neutrophils, a type of white blood cell essential for fighting infection. Chemotherapy can significantly reduce neutrophil counts, a condition known as neutropenia, which increases the risk of serious infections during cancer treatment. By boosting neutrophil production, Filgrastim helps reduce the duration and severity of chemotherapy-induced neutropenia, supporting the patient's ability to continue their cancer treatment on schedule. It is also used to help increase white blood cell counts in certain other conditions, including before stem cell collection for transplantation, where it helps mobilize stem cells from the bone marrow into the bloodstream. Unlike some longer-acting formulations, Filgrastim typically requires daily injections for a period following chemotherapy, as directed by a healthcare provider, until neutrophil counts recover to a safe level. Regular monitoring, including blood counts, helps track the patient's response and ensure the treatment is working as intended to support immune function during cancer treatment. Many patients experience meaningful reduction in infection risk and are better able to maintain their planned chemotherapy schedule with the support of Filgrastim. As with all supportive cancer care medications, Filgrastim should be administered under the guidance of an experienced oncology healthcare team as part of a comprehensive treatment plan.